Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection
暂无分享,去创建一个
[1] Simon Tiberi,et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline , 2016, European Respiratory Journal.
[2] S. Field,et al. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin. , 2016, Chest.
[3] R. Wilson,et al. The antimicrobial susceptibility of non-tuberculous mycobacteria. , 2016, The Journal of infection.
[4] P. Flume. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[5] Ming-wu Li,et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] D. R. Prevots,et al. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. , 2015, Clinics in chest medicine.
[7] F. Silveira,et al. Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients , 2015, Transplant infectious disease : an official journal of the Transplantation Society.
[8] L. Kremer,et al. In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[9] R. Wallace,,et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.
[10] N. Høiby,et al. Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis , 2014, Respiratory Research.
[11] J. Nick,et al. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. , 2014, Annals of the American Thoracic Society.
[12] D. Falzon,et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies , 2014, BMJ Open.
[13] C. Daley,et al. In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial Disease , 2012, Antimicrobial Agents and Chemotherapy.
[14] H. Steel,et al. Clofazimine: current status and future prospects. , 2012, The Journal of antimicrobial chemotherapy.
[15] John D. Mitchell,et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] Harminder Singh,et al. Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur). , 2011, Leprosy review.
[17] E. Y. Kim,et al. Treatment Outcome of Combination Therapy Including Clarithromycin for Mycobacterium avium Complex Pulmonary Disease , 2011, The Korean journal of internal medicine.
[18] Young Kil Park,et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. , 2011, American journal of respiratory and critical care medicine.
[19] Jiann-Hwa Chen,et al. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. , 2010, International journal of antimicrobial agents.
[20] M. Raffeld,et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. , 2008, American journal of respiratory and critical care medicine.
[21] P. Sexton,et al. Susceptibility to nontuberculous mycobacterial lung disease , 2008, European Respiratory Journal.
[22] Robert Horsburgh,et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.
[23] Mikio Oka,et al. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. , 2007, Respiratory medicine.
[24] Yoshihiro Kobashi,et al. The Microbiological and Clinical Effects of Combined Therapy according to Guidelines on the Treatment of Pulmonary Mycobacterium avium Complex Disease in Japan – Including a Follow-Up Study , 2006, Respiration.
[25] S. Field,et al. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. , 2003, Chest.
[26] Ji‐Hyun Lee,et al. Nontuberculous Mycobacteria , 2003 .
[27] J. Igual,et al. Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[28] R. Chaisson,et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic: Mycobacterium avium complex disease in patients with HIV infection , 1997, AIDS.
[29] J. Arbiser,et al. Clofazimine: a review of its medical uses and mechanisms of action. , 1995, Journal of the American Academy of Dermatology.
[30] M. Caldwell,et al. Epidemiology of disseminated nontuberculous mycobacterial disease in children with acquired immunodeficiency syndrome. , 1993, The Pediatric infectious disease journal.
[31] B. Dautzenberg,et al. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes. , 1991, Tubercle.
[32] J. Garrelts,et al. Clofazimine: A Review of its Use in Leprosy and Mycobacterium Avium Complex Infection , 1991, DICP : the annals of pharmacotherapy.
[33] Horsburgh Cr,et al. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). , 1989 .
[34] R. Selik,et al. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). , 1989, The American review of respiratory disease.
[35] D. Snider,et al. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. , 1987, The American review of respiratory disease.
[36] A. Fauci,et al. Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. , 1987, The Journal of infectious diseases.
[37] P. Stradling,et al. Potentially serious side-effects of high-dose twice-weekly rifampicin* , 1971, Postgraduate medical journal.
[38] P. Stradling,et al. Potentially Serious Side Effects of High-dose Twice-weekly Rifampicin , 1971, British medical journal.